Disorders of the Nervous System

Genetic Variations in the Serotonergic System Mediate a Combined, Weakened Response to SSRI Treatment: A Proposed Model\(^1,2\)

Adam Pettitt\(^1,2,3\)

DOI: http://dx.doi.org/10.1523/ENEURO.0032-14.2015

\(^1\)Department of Psychology, University of Oregon, Eugene, Oregon 97403, \(^2\)Department of Biology, Western Oregon University, Monmouth, Oregon 97361, and \(^3\)Department of Psychology, Western Oregon University, Monmouth, Oregon 97361

Abstract

Individuals with the short (S) allele in the promoter region of the serotonin transporter gene (5-HTTLPR) show a less favorable response to selective serotonin reuptake inhibitor (SSRI) treatment than individuals with the long (L) allele. Similarly, individuals with the C(-1019)G allele for the mutation found in the promoter region of the serotonin 1A receptor gene (5-HTR1A) have shown blunted responses to SSRI treatment when compared with individuals lacking this polymorphism. While these findings have been replicated across multiple studies, only two studies to date have reported data for a gene–gene interaction associated with response to SSRI treatment. Both of these studies reported a combined effect for these genotypes, with individuals homozygous for the L allele and the C allele (5-HTTL/L–1A/C) reporting the most favorable response to SSRI treatment, and individuals homozygous for the S allele and the G allele (5-HTT S/S–1AG/G) reporting the least favorable response to SSRI treatment. Additionally, no neural mechanisms have been proposed to explain why this gene–gene interaction has been observed. To that end, this article provides a review of the relevant literature associated with these polymorphisms and proposes a feasible model that describes a genotype-dependent modulation of postsynaptic serotonin signaling associated with the 5-HTT and 5-HTR1A genes.

Key words: 5-HT1A; 5-HTTLPR; depression; psychopharmacology; serotonin; SSRI

Significance Statement

Approximately forty percent of individuals that seek pharmacological treatment for depression do not initially respond to selective serotonin reuptake inhibitor (SSRI) antidepressants. Past research has attempted to determine if specific mutations in genes associated with the serotonergic system can help to predict response to antidepressant treatment; however, results have been inconclusive. Additionally, very little research has examined how multiple mutations can cause a combined, reduced response to SSRI antidepressant treatment. This article provides a review of the relevant literature, offers a model for why individuals with multiple mutations in the serotonergic system show a blunted response to SSRIs, and provides a basis for further research regarding genotype-dependent response to antidepressant treatment.

Introduction

Major depressive disorder (MDD) is a mental disorder that will affect an estimated 16% of the world population...
(Kessler et al., 2003). Of those individuals who seek treatment, approximately one-third of patients do not respond to antidepressant therapies (Fava and Davidson, 1996; Fava, 2003; Papakostas et al., 2006; Trivedi et al., 2006). Due to the high prevalence of MDD, and its associated healthcare costs, there has been a dramatic increase in the amount of money spent on both the prevention and treatment of this disease (Wang et al., 2003; Halfin, 2007). Because of these expenses, researchers have sought to better tailor treatments to individuals in hopes of reducing the vast resources expended pursuing effective treatment options. One proposal for reducing overall treatment cost is via genetic testing, which could help to predetermine which individuals will favorably respond to specific treatment types (Rausch et al., 2002). Unfortunately, further knowledge in regard to the underlying mechanisms by which individual genotypes are expected to interact with various drugs is necessary before genetic-testing techniques can be implemented (Serretti et al., 2009). Currently, much of the research being conducted on depression focuses on a class of signaling molecules known as neurotransmitters.

Reduced amounts of the monoamine neurotransmitter serotonin [5-hydroxytryptamine (5-HT)] is thought to be a predisposing factor for susceptibility to depression (Murphy et al., 1998). Additionally, short-term depletion of tryptophan, a biochemical precursor for 5-HT, leads to decreased serotonin levels, which can mediate relapses in previously depressed patients (Booij and Van der Does, 2011; Yatham et al., 2012; Young, 2013). In the brain, serotonin is produced by a subset of neurons located in the raphe nuclei (RN); however, axons extending from the RN innervate large areas of the brain, including the prefrontal cortex, hippocampus, hypothalamus, and amygdala (Peyron et al., 1998; Homung, 2003). These serotonergic projections modulate a multitude of behavioral responses, including sleep circadian rhythms, satiety levels, and mood (Bauer et al., 2002; Kranz et al., 2010; Homberg and Lesch, 2011); disruptions within these pathways have been linked to depressive symptoms (Holmes, 2008; Albert et al., 2014).

While serotonin has been implicated as an important biological factor in depression, many other factors, such as environmental stress and genetic makeup, can contribute to susceptibility to depression (Pittenger and Duman, 2008; Jasinska et al., 2012). The most widely studied mutation in the serotonin system is a variation in the length of the promoter region, known as the promoter region of the serotonin transporter protein (5-HTTLPR), located upstream of the serotonin transporter gene (SLC6A4; Murphy et al., 2004). Varying numbers of repeated elements are associated with different alleles; the “long” allele (5-HTTL*) has 16 repeat elements, while the “short” allele (5-HTT5) has 14 repeat elements. The 5-HTT5 allele is associated with a twofold increase in the basal serotonin transporter protein (5-HTT) transcription rate when compared with the 5-HTT5 allele, due to increased transcription factor binding of the 5-HTT promoter region (Maier and Zobel, 2008).

The presence of the 5-HTT5 allele has been associated with an increased susceptibility to depression in multiple studies. Interestingly, this increased susceptibility to depression exists only when preceded by stressful life events, suggesting that susceptibility to depression is mediated by both genetic and environmental factors (Caspi et al., 2003; Risch et al., 2009; Goldman et al., 2010; Uher and McGuffin, 2010; Karg et al., 2011). As well as being linked with increased susceptibility to depression, individuals with the 5-HTT5 allele in the 5-HTTLPR have also been shown to be less responsive to selective serotonin reuptake inhibitor (SSRI) treatment than individuals with the 5-HTT* allele (Smits et al., 2004; Porcelli et al., 2012).

In addition to the 5-HTTLPR polymorphism, a single nucleotide polymorphism in the promoter region of the serotonin 1A autoreceptor (5-HT1A) serotonin receptor gene (5-HTR1A) is also associated with depressive phenotypes. The G allele associated with this polymorphism, also known as C(-1019)G or rs6296, has been linked to a blunted response to SSRI treatment (Parsey et al., 2006b, 2010). As both of these polymorphisms are located within the promoter regions of each gene, the transcription rate of both the 5-HTT and the 5-HT1A receptor is altered when these alleles are present (5-HTT5 and 5-HT1A*), respectively. These altered transcription rates lead to altered transporter and receptor expression, and are a possible explanation for why these polymorphisms cause blunted responses to SSRI antidepressant therapy.

While many studies have examined the association between one polymorphism genotype and the response to SSRI treatment, only two studies to date (Arias et al., 2005; Hong et al., 2006) have accounted for a gene–gene interaction associated with treatment response. These studies showed a combined genotype effect for SSRI response, suggesting that some of the discrepancies found in other studies (Kraft et al., 2007; Dogan et al., 2008; Wilkie et al., 2008), which focused solely on one polymorphism, could be attributed to the omission of other genotypes. While there was a gene–gene interaction of 5-HT1A and 5-HTTLPR polymorphisms reported in both studies (Arias et al., 2005; Hong et al., 2006), no underlying mechanism has been offered as an explanation for why these findings were observed.

The purpose of this review is to provide a background on studies relevant to these polymorphisms and to propose a neural model that could account for the combined effect noted in these two studies. The neural model is based on alterations in the transcriptional regulation of the 5-HTT and the 5-HT1A receptor genes, with the 5-HTT5 allele causing a reduction in transcription rate of the 5-HTT and the 1A* allele causing an increase in the transcription rate of the 5-HT1A receptor. Ultimately, the model hypothesizes how these altered transcription rates
affect the amount of extracellular serotonin available for postsynaptic signaling and predicts a genotype-dependent response to SSRI antidepressant treatment.

**Serotonin transporter protein**

5-HTT, which is encoded by the human SLC6A4 gene, is thought to be the main mechanism by which serotonin is removed from the synapse (Homberg et al., 2007; Murphy and Lesch, 2008). While some mutations in the SLC6A4 gene have been shown to cause significant impairments in response to SSRI treatment (Smits et al., 2004), the majority of studies have focused on polymorphisms within 5-HTTLPR. In addition to the previously mentioned 5-HTTL and 5-HTTS polymorphisms, the 5-HTTLPR can be further modified by another allele, the 5-HTTLG allele (Hu et al., 2006; Murphy et al., 2013). This 5-HTTLG allele is associated with decreased transcription rates that could be equivalent to the 5-HTTS allele. In other words, individuals with the 5-HTTLG genotypes could have a twofold increase in the expression of 5-HT when compared to individuals with the 5-HTTL or 5-HTTS allele.

This twofold increase in expressed 5-HTT increases the amount of 5-HT removed from the synapse, also by a factor of two (Lesch et al., 1996; Bengel et al., 1998; Montañez et al., 2003; Homberg et al., 2007). Perhaps paradoxically, however, 5-HTT knock-out studies have shown there are no discernible differences in extracellular 5-HT concentrations in mice with half the amount of normally expressed 5-HTT (5-HTT−/−) compared with mice with normal 5-HTT (5-HTT+/+). This twofold increase in expressed 5-HTT increases the amount of 5-HT removed from the synapse, also by a factor of two (Lesch et al., 1996; Bengel et al., 1998; Montañez et al., 2003; Homberg et al., 2007). Perhaps paradoxically, however, 5-HTT knock-out studies have shown there are no discernible differences in extracellular 5-HT concentrations in mice with half the amount of normally expressed 5-HTT (5-HTT−/−) compared with mice with normal 5-HTT (5-HTT+/+). However, studies have shown that 5-HT reuptake is also carried out by other monoamine transporters (e.g., dopamine, norepinephrine), which could compensate for the reduced uptake in 5-HTT−/− mice (Shen et al., 2004). However, studies have shown significantly higher extracellular 5-HT concentrations in mice expressing no 5-HTT (5-HTT−/−) compared to 5-HTT+/− and 5-HTT+/+ mice, demonstrating that other monoamine transporters account for only a minimal amount of 5-HT reuptake (Mathews et al., 2004; Shen et al., 2004; Homberg et al., 2007).

Another explanation for the similarities in 5-HT concentration in both 5-HTT+/− and 5-HTT−/− mice is that basal firing rates of medial RN 5-HT neurons were reduced by 36% in 5-HTT−/− mice when compared to their homozygous 5-HTT+/− littermates (Gobbi et al., 2001). This reduced firing rate is attributed to the negative feedback mechanism mediated by 5-HT1A receptors, which alter the amount of 5-HT being released in direct response to how much 5-HT is being removed by the transporter (Fabre et al., 2000). This effect on the signaling pathway is thought to play a large part in patient response to antidepressant treatment, which is why the most widely prescribed antidepressant pharmacological agents (SSRIs) impinge on the 5-HTT.

**5-HTT and SSRI**

SSRIs are thought to inhibit the reuptake of 5-HT by binding to the active site of the extracellular hydrophobic region of the 5-HTT, effectively reducing the uptake of extracellular 5-HT (Murphy et al., 2004). As the 5-HTTS allele is associated with a reduction in the transcription rate of the 5-HTT by a factor of two, neurons with at least one 5-HTTS allele express half the amount of 5-HTT when compared with neurons with the homozygous 5-HTTL/L genotype. Because fewer 5-HTTs are available, studies have demonstrated that neurons expressing the 5-HTTS allele take approximately double the amount of time to remove 5-HT from the synapse when compared with neurons expressing 5-HTTL alleles (Lesch et al., 1996; Bengel et al., 1998; Montañez et al., 2003; Homberg et al., 2007). However, to determine 5-HT reuptake rates, the majority of these studies exogenously add 5-HT to the surrounding synapses. These results may not accurately represent the true nature of what is occurring at the synapse following SSRI treatment.

As previously stated, rodents with reduced expression of 5-HTT had no discernible differences in extracellular 5-HT prior to SSRI treatment. This, coupled with the observation that 5-HTT−/− mice show reduced serotoninergic firing rates (Gobbi et al., 2001), provides a possible explanation for what is occurring at the synapse after 5-HTT inhibition. Following SSRI treatment, if the same proportion of 5-HTTs are blocked in both 5-HTT+/− and 5-HTT+/+, then less 5-HT is ultimately released into the synapse. This is due to the 5-HT−/− neurons having reduced amounts of serotonin being released because of lower firing rates. Ultimately, because less 5-HT is being released into the synapse in 5-HTT−/− neurons, 5-HTT+/− neurons will have a larger increase in extracellular 5-HT after 5-HTT reuptake inhibition when compared with extracellular concentrations of 5-HT in 5-HTT+/− neurons. Supporting this proposed mechanism, subsequent to reuptake inhibition, 5-HTT+/+ mice had significantly higher extracellular 5-HT concentrations than 5-HTT+/− mice (Shen et al., 2004).

These results yield a possible explanation for why depression studies have reported an association between 5-HTTSS individuals and blunted SSRI treatment response (Smeraldi et al., 1998; Serretti et al., 2007; Huez-Diaz et al., 2009; Porcelli et al., 2012). Participants with differing genotypes receiving the same amount of SSRI should respond differently to treatment. This is mainly because individuals with the 5-HTTL allele would have a higher 5-HT concentration following SSRI treatment and, subsequently, more 5-HT postsynaptic signaling than individuals with the 5-HTTS allele. Corroborating this, individuals with the 5-HTTS allele showed reduced response to SSRI treatment when compared with individuals with the 5-HTTL allele. However, when the dosage of the SSRI was increased in individuals with the 5-HTTS allele, these individuals showed favorable responses that were similar to individuals with the 5-HTTL allele (Rausch et al., 2002). This increased dosage would lead to increased circulating SSRI levels. Ultimately, as more 5-HTTs are inhibited from the increased circulating levels of the SSRI, more 5-HT is kept in the synapse. This could compensate for the reduced amount of extracellular 5-HT in neurons expressing...
fewer 5-HTTs following SSRI treatment (Gartside et al., 1995), resulting in a reduction of depressive symptoms.

However, this initial increase in extracellular 5-HT levels does not fully explain SSRI mechanisms in their entirety; if reuptake inhibition were the only mechanism occurring, a response to SSRI treatment would happen almost instantaneously. Instead, patients report an initial response somewhere between 4 and 8 weeks after beginning treatment (Steimer et al., 2001; Gibbons et al., 2012). Many researchers implicate the downregulation of the 5-HT1A receptor as the most probable cause for this delay in response (Trivedi et al., 2006; Catapano and Manji, 2007; Hannon and Hoyer, 2008). While past antidepressant treatment options have been generally geared toward the 5-HTT, recently developed pharmacological agents have been aimed at other aspects of the serotonergic system, such as the 5-HT1A receptor (Lladó-Pelfort et al., 2010).

5-HT1A

Recently, the 5-HT1A receptor has been implicated in both susceptibility to depression and as a factor moderating the response to SSRI treatment (Blier, 2010; Richardson-Jones et al., 2010, 2011; Donaldson et al., 2013). The serotonin 1A receptor is a presynaptic autoreceptor in the RN, and a postsynaptic heteroreceptor in the amygdala, cortex, hippocampus, and hypothalamus (Soteló et al., 1990; Burnet et al., 1995; Riad et al., 2000). The serotonin 1A receptor is a pertussis toxin-sensitive heterotrimeric G-protein-coupled receptor (GPCR), which is coupled negatively to adenylyl cyclase (So-

telo et al., 1990; Burnet et al., 1995; Riad et al., 2000). The serotonin 1A receptor is a pertussis toxin-sensitive heterotrimeric G-protein-coupled receptor (GPCR), which is coupled negatively to adenylyl cyclase (Catapano and Manji, 2007). Ligand binding to this class of GPCRs has been shown to open potassium channels and close calcium channels, leading to hyperpolarization of the neuron and ultimately to inhibition of the cell (Rotondo et al., 1997; Hannon and Hoyer, 2008).

Serotonin 1A receptors are the main somatodendritic autoreceptors that mediate the negative-feedback mechanism in serotonergic raphe neurons (Riad et al., 2000). Discrete portions of the RN have serotonergic axons that extend to different regions of the brain (Bang et al., 2012). Within each of these discrete clusters of neurons, shorter axons extend from the RN, synapse onto other serotonergic axons, and inhibit the axons extending to other portions of the brain (Vasudeva et al., 2011). This feedback mechanism works by inducing a series of cascade events that regulate the amount of serotonin being released based on current extracellular 5-HT concentrations. In other words, a decrease in extracellular 5-HT will result in reduced 5-HT1A autoreceptor binding, less cell hyperpolarization, disinhibition of the serotonin neuron, and increased 5-HT release at the axon terminal. Conversely, an abundance of extracellular 5-HT will result in increased 5-HT1A autoreceptor binding, increased cell hyperpolarization, neuronal inhibition, and reduced 5-HT release at the axon terminal (Koek et al., 1998; Gobbi et al., 2001).

5-HT1A genes

The 5-HT1A receptor is encoded by the intronless gene 5HTR1A, which is found on chromosome 5q11.2-13 (Kobilka et al., 1987; Albert et al., 1990). Similar to the 5-HTTLPR region in the 5-HTT gene, the 5HTR1A gene contains a promoter sequence. However, the interactions between the promoter region and transcription factors associated with this area are more complex (Parks and Shenk, 1996; Albert et al., 2011). Pet-1 is a transcription factor, expressed only in raphe–specific cells, that binds to several Pet-1 binding sites upstream of the 5HTR1A gene (Jacobsen et al., 2011). Because Pet-1 is only expressed in serotonergic neurons found in the raphe nuclei, all 5-HT1A receptors produced by Pet-1 are considered autoreceptors. More broadly, 5-HT1A receptors—both heteroreceptors and autoreceptors—are selectively expressed only on neuronal cells via the repressors Freud-1, Freud-2, and REST (Ou et al., 2000; Lemonde et al., 2004). While REST restricts the expression of 5-HT1A receptors only in non-neuronal cells. Freud-1/2 repressors act to restrict 5-HT1A receptor expression in both non-neuronal and neuronal cells (Albert, 2012). More specifically, Freud-1/2 repressors act to inhibit the expression of 5-HT1A receptors in the brain and the CNS.

Another transcription factor regulating the expression of 5HTR1A is NUDR/Deaf1, which is unique in that its function changes depending on which cell type it is expressed in. In non-raphe neurons, this transcription factor acts as an enhancer, which upregulates the amount of postsynaptic heteroreceptors present on the cell membrane (Czesak et al., 2006). In direct juxtaposition, the same transcription factor (Deaf1) acts as a repressor in RN serotonergic cells. A study supporting this reported a 50% increase in 5-HT1A autoreceptor expression in the dorsal and medial RN following removal of the Deaf1 repressor (Czesak et al., 2012). This relatively recent discovery has elucidated some of the mechanisms surrounding 5-HT1A receptor regulation and 5-HT1A receptor binding in depression, as multiple conflicting studies report both increased and decreased 5-HT1A binding in depressed individuals (Parsey et al., 2010).

5-HT1A and depression

Many of the first studies implicating 5-HT1A receptors in depression consisted of postmortem studies of depressed suicidal patients (Stockmeier et al., 1998; Arango et al., 2001). Discrepancies arose, however, as these studies reported both decreased and increased 5-HT1A binding in suicidal individuals. These studies have been criticized for their very low sample size and high interperson variability; more specifically, age varied widely among subjects in these postmortem studies. As positron emission tomography (PET) imaging of the 5-HT1A selective antagonist [11C]WAY-100635 has shown significant decreases in 5-HT1A receptor binding with increased age (Tauscher et al., 2001), this has cast some doubt on the reliability of these findings.

PET scanning is considered a more reliable method for determining the association of 5-HT1A binding with depression, as this technique allows for measurements of metabolic changes in live tissue (Sargent et al., 2000; Bhagwagar et al., 2004; David et al., 2005; Parsey et al., 2006a). Many of these studies reported findings that conflicted with one another, as some studies associated increased depressive symptoms with reduced 5-HT1A
receptor binding (Drevets et al., 1999; Sargent et al., 2000). Others studies, however, reported that higher binding potentials were correlated with increased depressive symptoms and blunted SSRI treatment response (Parsey et al., 2006a, b, 2010; Miller et al., 2009; Richardson-Jones et al., 2010).

A possible reason for these discrepancies has been attributed to the C(-1019)G polymorphism located within an inverted repeat section recognized by the Deaf1 transcription factor (Jacobsen et al., 2011; Albert, 2012). As noted earlier, Deaf1 acts as an enhancer in non-raphe cells (increasing 5-HT1A heteroreceptor expression) and a repressor in raphe cells (decreasing 5-HT1A autoreceptors expression; Czesak et al., 2006; Czesak et al., 2012). This disruption in the expression of the 5-HT1A autoreceptor has been associated with decreased SSRI response (Serretti et al., 2004; Suzuki et al., 2004; Arias et al., 2005; Hong et al., 2006) and increased susceptibility to depression in adults directly following a stressful life event (Lemone et al., 2003; Parsey et al., 2010; Benedetti et al., 2011). Additionally, studies have revealed that individuals with the 5-HTTS/G genotype show reduced expression of the 5-HT1A autoreceptor, which could also account for an increased susceptibility to depression (David et al., 2005).

Studies using both genetic and neuroimaging techniques have found increased presynaptic 5-HT1A autoreceptor binding and increased 5-HT1A autoreceptor expression levels in affected patients with depression (Sargent et al., 2000; Bhagwagar et al., 2004) have reported reduced binding across postsynaptic 5-HT1A receptors. Interestingly, some studies (Parsey et al., 2006b) have reported an increase in postsynaptic 5-HT1A binding potentials associated with the 1A/G genotype. While this genotype does result in significant downregulation of the 5-HT1A heteroreceptor, increased 5-HT1A autoreceptor expression leads to increased extracellular 5-HT concentrations. This decrease in extracellular 5-HT concentrations is thought to lead to partial, compensatory upregulation of the postsynaptic 5-HT1A autoreceptor (Parsey et al., 2010; Albert, 2012). This compensation would account for the observed increased postsynaptic binding. In addition, increased 5-HT1A autoreceptor binding [especially due to the C(-1019)G polymorphism] has been correlated with a decreased response to SSRI treatment (Parsey et al., 2006b; Richardson-Jones et al., 2010). This blunted response in participants with the 1A/G genotype is attributed to decreased raphe inhibition due to higher 5-HT1A autoreceptor binding. This increased inhibition would ultimately lead to overall lower concentrations of extracellular 5-HT when compared with neurons from individuals with the 1A/G genotype (Albert et al., 2014).

Adding to this line of evidence are a number of studies in which mice have been transgenically bred to show normal, reduced, or no 5-HT1A receptors (1A/+, 1A/−, 1A/−/− mice, respectively; Donaldson et al., 2013). In a 2010 study, researchers (Richardson-Jones et al., 2010) developed a reversible method of tetracycline-dependent transcriptional suppressor-induced downregulation of 5-HT1A autoreceptors, but not 5-HT1A heteroreceptors. Mice induced to show lower levels of 5-HT1A presynaptic autoreceptors showed a markedly improved response to fluoxetine (SSRI) treatment in multiple depressive tests. Additionally, extracellular 5-HT concentrations 8 d after SSRI treatment were significantly higher in 1A−/− mice when compared with 1A+/− mice. Experiments using irreversible 5-HT1A knock-out mice have also reported a favorable antidepressant response in mice with reduced expression of 5-HT1A autoreceptors (Bortolozzi et al., 2012; Ferrés-Coy et al., 2013). These studies imply that modifications to the 5-HT1A receptors could be beneficial in the treatment and remission of depression.

Clinical implications

Many studies have reported that the administration of both 5-HT1A antagonists (Blier and Ward, 2003; Berney et al., 2008) and agonists (Koek et al., 1998; Papakostas et al., 2004) result in antidepressant effects in treatment-resistant depressive patients. Weak antagonists, such as pindolol, reportedly bind to 5-HT1A receptors without causing a reduction in 5-HT firing rates, while preventing further inhibition and, consequently, desensitization from occurring (Albert, 2012). Agonists, however, are thought to work via 5-HT1A autoreceptor firing, 5-HT1A autoreceptor downregulation, and disinhibition of the 5-HT neuron, resulting in increased raphe 5-HT firing (Rondon et al., 1997; Koek et al., 1998).

This 5-HT1A autoreceptor downregulation and raphe disinhibition, which can occur over a timespan of weeks, is thought to be one of the main pathways in which SSRIs mediate a reduction of depressive symptoms. It is also thought to account for the 4-8 week delayed response observed during SSRI treatment (Gartside et al., 1995; Blier, 2010; Richardson-Jones et al., 2010). As extracellular levels of 5-HT are increased in the synapse due to blocked 5-HTT, 5-HT1A receptors initially become desensitized with minutes of activation (Ferguson, 2001; Shehnoy and Lefkowitz, 2003). Consistent ligand binding of the 5-HT1A somatodendritic autoreceptor leads to compensatory downregulation of 5-HT1A autoreceptors and reduced gene expression, causing disinhibition of the raphe cells (Albert and Lemonde, 2004). This disinhibition has been shown to lead to increased raphe firing and higher extracellular 5-HT concentrations in the weeks following SSRI treatment (Richardson-Jones et al., 2010). As this is the case, some studies have shown that augmenting SSRI treatment with 5-HT agonists, or antagonists, helped to achieve a greater reduction in depressive symptoms in patients with treatment-resistant depression (Trivedi et al., 2006; Berney et al., 2008). Because both the 5-HT1A and 5-HTT genes have been implicated in response to antidepressant treatment, it is imperative that future research accounts for both genes, and that future treatments incorporate agents that act on both proteins.

5-HT1A and 5-HTTLPR combined effect

Grounds for a relevant model

Because antidepressant augmentations that impinge upon 5-HT1A receptors have been shown to be effec-
tive form of treatment for depression, polymorphisms within this region have become a topic of interest during the past decade (Suzuki et al., 2004; Drago et al., 2008). The previously mentioned C(-1019)G polymorphism is one of the most widely studied mutations in the 5-HT1A receptor, and many studies (Hong et al., 2006; Malagutti et al., 2011) have shown that the $1^{{\text{AG/G}}}$ genotype mediates an attenuated response to antidepressant treatment, although it should be noted that not all studies have found an association with this polymorphism and antidepressant response (Xu et al., 2012). Similarly, while several studies have demonstrated that the 5-HTTLPR polymorphism modulates the response to SSRI treatment (Smeraldi et al., 1998; Rausch et al., 2002; Huezo-Diaz et al., 2009), there are still multiple studies that have reported no association between the 5-HTTLPR genotype and response to SSRIs (Kraft et al., 2007; Dogan et al., 2008; Wilkie et al., 2008). There are many factors that could lead to the discrepancies found among these studies, which have been reviewed elsewhere (Serretti et al., 2007; Porcelli et al., 2012). However, it is possible that other polymorphisms, not accounted for, could cause there to be no observable difference in SSRI response. Both polymorphisms have a high population prevalence in Caucasians [5-HTTLPR $L^{{\text{L/L}}}$ = 0.331, 5-HTTLPR $L^{{\text{S/S}}}$ = 0.474, 5-HTTLPR $L^{{\text{S/L}}}$ = 0.195 (Odgerel et al., 2013); $1^{{\text{A}}}$ = 0.675, $1^{{\text{AG}}}$ = 0.325 (Drago et al., 2008)]. Considering how both of these polymorphisms can alter the response to SSRI treatments, it is highly possible that these unmeasured genotypes have been a confounding factor in previous studies.

A search of the relevant literature yielded only two studies (Arias et al., 2005; Hong et al., 2006) that have examined the relationship between both polymorphisms and the response to SSRI treatment. In both studies, a combined effect was reported. Arias et al. (2005) observed that participants with the 5-HTTLPR $S^{{\text{S/S}}}$–$1^{{\text{AG/G}}}$ genotype (each independently shown to be the least responsive to SSRI treatment) reported a significantly less favorable response to SSRI administration than any other genotype. Conversely, Hong et al. (2006) found that of all the genotypes tested for SSRI response, patients with the 5-HTTLPR $L^{{\text{L/L}}}$–$1^{{\text{A/C/C}}}$ genotype (each independently shown to be the most responsive to SSRI treatment) responded significantly better than participants with any of the other genotypes. These results, along with research that associates the 5-HTT and 5-HT1A polymorphisms with a combined increased susceptibility to depression (Zhang et al., 2009), demonstrate that a more nuanced approach is necessary for determining the relationship between SSRI response and genotype. While these studies did report a gene–gene response to SSRI treatment, no neural model was offered as to why these effects were observed. Additionally, no mechanism, to date, has been proposed as to why these genotypes show a combined response to antidepressant treatment.

Model

Based on the knowledge currently available about the two polymorphisms, a model is presented that might account for the gene–gene interaction effect and provide a framework to guide future work in this area. As noted above, 5-HTTLPR $L^{{\text{L/L}}}$–$1^{{\text{AG/G}}}$ mice with reduced amounts of expressed 5-HTT, analogous to the 5-HTTLPR $S^{{\text{S/S}}}$ genotype in humans, owing to their reduced expression of 5-HTT (Murphy et al., 2001; Murphy and Lesch, 2008; Kaluuff et al., 2010), show no discernible differences in extracellular 5-HT concentration when compared with 5-HTTLPR $L^{{\text{L/L}}}$–$1^{{\text{A/C/C}}}$ mice (analogous to the 5-HTTLPR $S^{{\text{S/S}}}$ genotype in humans; Mathews et al., 2004). Following SSRI treatment, increases in extracellular 5-HT concentrations were larger in 5-HTTLPR $L^{{\text{L/L}}}$–$1^{{\text{A/C/C}}}$ mice than increases in extracellular concentrations observed in 5-HTTLPR $L^{{\text{L/L}}}$–$1^{{\text{A/G/G}}}$ mice (Shen et al., 2004).

In other murine models, $1^{{\text{A}}}$ mice with a higher expression of 5-HT1A autoreceptors, analogous to the 5-HTTLPR $S^{{\text{S/S}}}$ genotype in humans, express higher 5-HT1A presynaptic binding and a weakened response to SSRI treatment when compared with the $1^{{\text{A}}}$ mice (Richardson-Jones et al., 2010). This blunted response is attributed to larger amounts of presynaptic terminal inhibition due to increased 5-HT1A autoreceptor binding (Parsley et al., 2010). Additionally, after SSRI treatment and somatodendritic downregulation of 5-HT1A autoreceptors, 1A$^{{\text{A/G/G}}}$ mice initially expressing lower numbers of 5-HT1A autoreceptors had markedly higher extracellular 5-HT concentrations than that of their 1A$^{{\text{A/C/C}}}$ littermates (Richardson-Jones et al., 2010). These results together form the basis for the proposed model, which describes a genotype-dependent modulation of postsynaptic serotonin signaling associated with the 5-HTT and 5HT1A genes (Figs. 1, 2).

5-HTTLPR $L^{{\text{L/L}}}$–$1^{{\text{A/C/C}}}$ genotype

While there would be no marked difference in initial extracellular 5-HT levels between 5-HTTLPR genotypes, after SSRI treatment high amounts of extracellular 5-HT in the synapse would be present, specifically in contrast with individuals with the 5-HTTLPR $S^{{\text{S/S}}}$ genotype. The high amounts of extracellular 5-HT would then bind to the low amounts of 5-HT1A autoreceptors (when compared with the $1^{{\text{A/G/G}}}$ genotype) on the presynaptic cell and would lead to a mild-to-moderate amount of inhibition. After downregulation 5-HT1A autoreceptors after somatodendritic 5-HT1A receptor binding, larger amounts of serotonin would be released into the synapse when compared to the $1^{{\text{A/G/G}}}$ genotype as demonstrated by Richardson-Jones et al., 2010). Due to the high amounts of extracellular 5-HT from 5-HT binding and increased 5-HT release from reduced presynaptic terminal inhibition, the largest increase in 5-HT levels would occur in these individuals. This genotype is hypothesized to result in the highest amount of postsynaptic 5-HT signaling and would show the most favorable response to SSRI treatment.

5-HTTLPR $L^{{\text{L/L}}}$–$1^{{\text{A/G/G}}}$ genotype

After SSRI treatment, individuals with this genotype would initially have the same increase in extracellular 5-HT levels as the 5-HTTLPR $L^{{\text{L/L}}}$–$1^{{\text{A/C/C}}}$ genotype, but due to the higher number of 5-HT1A autoreceptors there would be an increased amount of inhibition in the presynaptic terminal, leading to low amounts of 5-HT released. After somato-
Figure 1 Pre-SSRI treatment. Diagram depicting extracellular 5-HT concentration, 5-HTT expression, and 5-HT1A receptor expression across the 5-HTTLPR and 5-HTR1A genotypes. A, B, Increased expression of 5-HTT due to the 5-HTTL/L genotype. C, D, Decreased expression of 5-HTT due to the 5-HTTL/S genotype. A, C, Reduced expression of 5-HT1A due to the 1A/C/C genotype. B, D, Reduced expression of 5-HT1A due to the 1A/G/C genotype. While studies have demonstrated that there are fewer 5-HT1A expressed receptors in individuals with the 5-HTTS/S genotype (David et al., 2005), for the sake of simplicity in the model, no interaction is assumed between the two polymorphisms.

Figure 2 Post-SSRI treatment. Diagram depicting extracellular 5-HT concentration, 5-HTT expression, and 5-HT1A receptor expression across the 5-HTTLPR and 5-HTR1A genotypes after long-term SSRI treatment. Subsequent to somatodendritic downregulation of 5-HT1A autoreceptors, disinhibition of raphe neurons causes an increase in 5-HT release. A-C, However, genotypes that express fewer 5-HTTs or higher numbers of 5-HT1A receptors (B, C) show a reduced increase in extracellular 5-HT concentration when compared with the genotype that has higher 5-HTT levels and lower numbers of 5-HT1A receptors (A). D, The genotype expressing both reduced levels of 5-HTT and higher numbers of 5-HT1A receptors shows the smallest increase in extracellular levels of 5-HT.
dendritic downregulation, only a moderate increase in 5-HT levels would be observed, owing to the high serotonin concentration from the blocked 5-HTT and the low amount of 5-HT released due to the high 5-HT1A autoreceptor density. This genotype is hypothesized to result in a moderate amount of postsynaptic 5-HT signaling and show an intermediate response to SSRI treatment.

5-HTTSS/1AAG/G genotype

After SSRI treatment, individuals with the 5-HTTSS/1AAG/G genotype would have a small increase in extracellular 5-HT concentrations when compared with the 5-HTTL/L genotype. This small amount of 5-HT binding to the low number of 5-HT1A autoreceptors would lead to a smaller magnitude in the downregulation of the somatodendritic cell, when compared with downregulation from the 5-HTTL/L genotypes. This reduced amount of downregulation, and consequently the low amounts of disinhibition, would be offset, however, by the reduced expression of presynaptic 5-HT1A autoreceptors already present due to the 1AG/G genotype, resulting in a moderate increase in 5-HT levels. This genotype is hypothesized to result in a level of postsynaptic 5-HT signaling and show an intermediate response to SSRI treatment (possibly similar to that of the 5-HTTSS/1AC/C genotype).

5-HTTL/L–1AG/G genotype

Following SSRI treatment, individuals with the 5-HTTL/L–1AG/G genotype would have the same increase in extracellular 5-HT concentrations as the genotype 5-HTTSS/1AC/C, but, due to the increased number of 5-HT1A autoreceptors present, a higher amount of presynaptic inhibition would occur. In addition, once downregulation of the somatodendritic 5-HT1A receptors occurred (similar to that of the 5-HTTSS/1AC/C genotype), less 5-HT would be released into the synapse due to the higher density of the 5-HT1A autoreceptors inhibiting the presynaptic terminal. The small amount of extracellular serotonin from 5-HTT binding, combined with the small amounts of 5-HT being released due to high 5-HT1A autoreceptor density, would lead to the smallest increase in 5-HT levels. This genotype is hypothesized to result in the least amount of postsynaptic 5-HT signaling and would show the least favorable response to SSRI treatment.

Discussion

The proposed model predicts that the 5-HTTL/L–1AC/C genotype will produce the highest amount of postsynaptic 5-HT signaling, that the 5-HTTL/L–1AG/G and 5-HTTSS/1AC/C genotypes will produce a moderate amount of postsynaptic 5-HT signaling, and that the 5-HTTSS/1AG/G genotype will produce the least amount of postsynaptic 5-HT signaling. In addition to predicting which individuals will respond more favorably to antidepressant treatments, this model can also be used to predict the temporal dynamics associated with response to treatment. More specifically, while the functional outcomes of the 5-HTTL/L–1AG/G and 5-HTTSS/1AC/C genotypes are predicted to be similar, these genotypes may behave differently before they reach equilibrium. Because the 5-HTTL/L–1AG/G genotype contains a high density of inhibitory 5-HT1A autoreceptors, the benefits of the SSRI treatment will be observed only after the autoreceptors have been downregulated. Only after the autoreceptors have been downregulated will the increase in extracellular 5-HT levels be detectable. In contrast, the 5-HTTSS/1AG/G genotype has a significantly lower density of inhibitory 5-HT1A autoreceptors. It is possible that the main benefits of SSRI treatment could be observed earlier than the 5-HTTL/L–1AG/G genotype, as the model predicts that the 5-HTTSS/1AC/C genotype relies less on somatodendritic downregulation of 5-HT1A autoreceptors and more on the initial inhibition of 5-HT reuptake. Future research can examine whether genotype moderates the temporal response to antidepressant treatment, as well as the end response.

Ultimately, the model predicts the response to SSRI treatment based on genotypic modulation of postsynaptic 5-HT signaling. This genotype-dependent modulation of postsynaptic serotonin signaling is important, as higher postsynaptic serotonin signaling is associated with reduced depressive symptoms. This is, in part, thought to be due to the triggering of chemical cascades that ultimately results in both increased dendritic arborization and brain-derived neurotrophic factor (BDNF) expression within hippocampal cells (Nestler et al., 2002). Increased 5-HT signaling via SSRI treatment has been reported to enhance BDNF expression (Duan et al., 2004), which is associated with a reduction in depressive symptoms (Martinowich and Lu, 2008). It is because of these downstream pathways that 5-HT levels are implicated in both susceptibility to and treatment of depression, and why SSRIs, which increase postsynaptic 5-HT signaling, are effective in treating depression. This also explains why participants with the 5-HTTL/L–1AC/C genotype respond more favorably to SSRI treatment than other genotypes and why individuals with the 5-HTTSS/1AC/C genotype have poorer treatment response than those with other genotypes (Arias et al., 2005; Hong et al., 2006), as the modulated 5-HT increases associated with each genotype would alter induced BDNF expression.

Further research should be conducted to determine whether differences in BDNF expression, and other downstream responses associated with 5-HT signaling, are observed between individuals with differing genotypes, as this would add further support for the proposed model. Additionally, researchers have recently developed a 5-HT1A agonist (F15599) specifically targeted for 5-HT1A heteroreceptors (Lladó-Pelfort et al., 2010). Individuals with a blunted response to SSRI treatment due to genotype could benefit from 5-HT1A heteroreceptor agonist augmentation as it could compensate for the marginal increase in extracellular 5-HT available for postsynaptic signaling.

While this model proposes an explanation for the gene–gene interaction observed by the two previously mentioned studies (Arias et al., 2005; Hong et al., 2006), it is insufficient to explain why some patients fail to respond to antidepressant treatment, whereas others who have a genetic predisposition never actually succumb to depression. This is due to the highly plastic nature of the sero-
tonin system, which can only compensate for a disruption in one aspect of the 5-HT system (Holmes, 2008). Extensive research is still necessary before widespread use of genetic testing in tailoring antidepressant treatment to individuals can be implemented, and other gene–gene interactions (including gene–gene–gene and gene–gene–environment interactions) should be studied further. This model advances the current understanding of how genotype can influence the neuronal response to antidepressants and can help to guide future research on the topic of SSRI response.

References
Albert PR (2012) Transcriptional regulation of the 5-HT1A receptor: implications for mental illness. Philos Trans R Soc Lond B Biol Sci 367:2402-2415. CrossRef Medline
Albert PR, Lemonde S (2004) 5-HT1A receptors, gene repression, and depression: guilt by association. Neuroscience 10:575-593. CrossRef Medline
Albert PR, Le François B, Millar AM (2011) Transcriptional dysregulation of 5-HT1A autoreceptors in mental illness. Mol Brain 4:21. CrossRef
Albert PR, Vahid-Ansari F, Luckhart C (2014) Serotonin-prefrontal cortical circuitry in anxiety and depression phenotypes: pivotal role of pre- and post-synaptic 5-HT1A receptor expression. Front Behav Neurosci 8:199. CrossRef Medline
Albert PR, Zhou QY, Van Tol HH, Bunzow JR, Civelli O (1990) Cloning, functional expression, and mRNA tissue distribution of the rat 5-hydroxytryptamine1A receptor gene. J Biol Chem 265:5825-5832. Medline
Arango V, Underwood MD, Boldrini M, Tamir H, Kassir SA, Hsiung S, Chen JQ, Mann JJ (2001) Serotonin 1A receptors, serotonin transporter binding and serotonin transporter mRNA expression in the brainstem of depressed suicide victims. Neuropsychopharmacology 25:892-903. CrossRef
Arias B, Catalán R, Gastó C, Gutiérrez B, Fañanás L (2005) Evidence for a combined genetic effect of the 5-HT1A(1A) receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram. J Psychopharmacol 19:166-172. CrossRef
Bang SJ, Jensen P, Dymeczi SM, Commons KG (2012) Projections and interconnections of genetically defined serotonin neurons in mice. Eur J Neurosci 35:85-96. CrossRef Medline
Bauer M, Heinz A, Whybrow PC (2002) Thyroid hormones, serotonin and mood: of synergy and significance in the adult brain. Mol Psychiatry 7:140-156. CrossRef Medline
Benedettì F, Radaelli D, Poletti S, Locatelli C, Dallaspezia S, Lorenzi C, Pirovano A, Colombo C, Smeraldi E (2011) Association of the C(−1019)G 5-HT1A promoter polymorphism with exposure to stressors preceding hospitalization for bipolar depression. J Affect Disord 132:297-300. CrossRef
Bengel D, Murphy DL, Andrews AM, Wichems CH, Feltner D, Heits A, Mössner R, Westphal H, Lesch K-P (1998) Altered brain serotonin homeostasis and locomotor insensitivity to 3,4-methylenedioxymethylamphetamine (“ecstasy”) in serotonin transporter-deficient mice. Mol Pharmacol 53:649-655. CrossRef
Bernet A, Nishikawa M, Benkelfat C, Debonnel G, Gobbi G, Diksic M (2008) An index of 5-HT synthesis changes during early antidepressant treatment: Δ[11C]methyl-l-tryptophan PET study. Neurochem Int 52:701-708. CrossRef Medline
Bhagwagar Z, Rabiner EA, Sargent PA, Grasby PM, Cowen PJ (2004) Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Mol Psychiatry 9:386-392. CrossRef
Blier P (2010) Altered function of the serotonin 1A autoreceptor and the antidepressant response. Neuron 65:1-2. CrossRef Medline
Blier P, Ward NM (2003) Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry 53:193-203. Medline
Booj L, Van der Does AJW (2011) Emotional processing as a predictor of symptom change: an acute tryptophan depletion study in depressed patients. Eur Neuropsychopharmacol 21:379-383. CrossRef Medline
Bortolozzi A, Castañé A, Semaková J, Santana N, Alvarado G, Cortés R, Ferrés-Coy A, Fernández G, Carmona MC, Toth M, Perales JC, Montefeltro A, Artigas F (2012) Selective siRNA-mediated suppression of 5-HT1A autoreceptors evokes strong anti-depressant-like effects. Mol Psychiatry 17:612-623. CrossRef Medline
Burnet PW, Eastwood SL, Lacey K, Harrison PJ (1995) The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain. Brain Res 676:157-168. Medline
Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R (2003) Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301:386-389. CrossRef Medline
Catapano LA, Manji HK (2007) G protein-coupled receptors in major psychiatric disorders. Biochim Biophys Acta 1768:976-993. CrossRef Medline
Czesak M, Lemonde S, Peterson EA, Rogaea C, Albert PR (2006) Cell-specific repressor or enhancer activities of de-1 at a serotonin 1A receptor gene polymorphism. J Neurosci 26:1864-1871. CrossRef Medline
Czesak M, Le François B, Millar AM, Doria M, Daigle M, Visvader JE, Anisman H, Albert PR (2012) Increased serotonin-1A (5-HT1A) autoreceptor expression and reduced raphe serotonin levels in deformed epidural autoregulatory factor-1 (de-1) gene knock-out mice. J Biol Chem 287:6615-6627. CrossRef Medline
David SP, Murthy NV, Rabiner EA, Munafò MR, Johnstone EC, Jacob R, Walton RT, Grasby PM (2008) A functional genetic variation of the serotonin (5-HT) transporter affects 5-HT1A receptor binding in humans. J Neurosci 25:2586-2590. CrossRef Medline
Dogan O, Yuksel N, Ergun MA, Yilmaz A, Ilhan MN, Karsiloğlu HE, Koc A, Menevse A (2008) Serotonin transporter gene polymorphisms and sertraline response in major depression patients. Genet Test 12:225-231. CrossRef Medline
Donaldson ZR, Nautiyal KM, Ahmari SE, Hen R (2013) Genetic approaches for understanding the role of serotonin receptors in mood and behavior. Curr Opin Neurobiol 23:399-406. CrossRef Medline
Drago A, Ronchi DD, Serretti A (2008) 5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Int J Neuropsychopharmacol 11:701-721. CrossRef Medline
Drevets W, Frank E, Price J, Kupfer D, Holt D, Greer P, Huang Y, Gautier C, Mathis C (1999) PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry 46:1375-1387. Medline
Duan W, Guo Z, Jiang H, Ladenheim B, Xu X, Cadet JL, Mattson MP (2004) Paroxetine retards disease onset and progression in Huntington mutant mice. Ann Neurol 55:590-594. CrossRef Medline
Fabre V, Beaufour C, Evrard A, Rioux A, Hanoun N, Lesch KP, Murphy DL, Lanfumey L, Hamon M, Martres MP (2000) Altered expression and functions of serotonin 5-HT1A and 5-HT1B receptors in knock-out mice lacking the 5-HT transporter. Eur J Neurosci 12:2299-2310. Medline
Fava M (2003) Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 53:649-659. Medline
Fava M, Davidson KG (1996) Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 19:179-200. Medline
Ferguson SSG (2001) Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 53:1-24. Medline
Ferrés-Coy A, Santana N, Castañé A, Cortés R, Carmona MC, Toth M, Montefeltro A, Artigas F, Bortolozzi A (2013) Acute 5-HT1A autoreceptor knockdown increases antidepressant responses and serotonin release in stressful conditions. Psychopharmacology 225:61-74. CrossRef
Gartside S, Umbers V, Hajós M, Sharp T (1995) Interaction between a selective 5-HT1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. Br J Pharmacol 115:1064-1070. Medline

Gibbons RD, Hur K, Brown C, Davis JM, Mann J (2012) Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry 69:572-579. CrossRef Medline

Gobbi G, Murphy DL, Lesch K-P, Blier P (2001) Modifications of the serotonergic system in mice lacking serotonin transporters: an in vivo electrophysiological study. J Pharmacol Exp Ther 296:987-995. Medline

Goldman N, Glei D, Lin Y, Weinstein M (2010) The serotonin transporter polymorphism (5-HTTLPR): allelic variation and links with depressive symptoms. Depress Anxiety 27:260-269. CrossRef Medline

Hafin A (2007) Depression: the benefits of early and appropriate treatment. Am J Manag Care 13:S92-S97. Medline

Hannon J, Hoyer D (2008) Molecular biology of 5-HT receptors. Behav Brain Res 195:198-213. CrossRef Medline

Holmes A (2008) Genetic variation in cortico-amygdala serotonin function and risk for stress-related disease. Neurosci Biobehav Rev 32:1293-1314. CrossRef Medline

Homberg JR, Lesch KP (2011) Looking on the bright side of serotonergic system. Neuroscience 146:1662-1676. CrossRef Medline

Hong C-J, Chen T-J, Yu YY-W, Tsai S-J (2006) Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwanese Chinese major depressive disorder. Pharmacogenomics J 6:27-33. CrossRef Medline

Horning J-P (2003) The human raphe nuclei and the serotonergic system. J Chem Neuroanat 26:331-343. Medline

Hu X-Z, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, Xu X, Arnold PD, Richter MA, Kennedy JL, Murphy DL, Goldman D (2006) Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 78:815-826. CrossRef Medline

Huezo-Diaz P et al. (2009) Moderation of antidepressant response by the serotonin transporter gene. Br J Psychiatry 195:30-38. CrossRef Medline

Jacobsen KK, Czesak M, Deria M, Le François B, Albert PR (2011) Region-specific regulation of 5-HT1A receptor expression by Pet-1-dependent mechanisms in vivo. J Neurochem 116:1066-1076. CrossRef Medline

Jasinska A, Lowry C, Burmeister M (2012) Serotonin transporter gene, stress and raphe-raphe interactions: a molecular mechanism of depression. Trends Neurosci 35:395-402. CrossRef Medline [Mismatch]

Kaluff AV, Olivier JDA, Nonkes LJP, Homberg JR (2010) Conserved role for the serotonin transporter gene in rat and mouse neurobehavorial endophenotypes. Neurosci Biobehav Rev 34:373-386. CrossRef Medline

Karg K, Burmeister M, Shedden K, Sen S (2011) The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch Gen Psychiatry 68:444-454. CrossRef Medline

Kessler RC, Berglund P, Demler O, et al. (2003) The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289:3095-3105. CrossRef Medline

Koblikka BK, Frielle T, Collins S, Yang-Feng T, Koblikka TS, Francke U, Lefkowitz RJ, Caron MG (1987) An intronless gene encoding a potential member of the family of receptors coupled to guanine nucleotide regulatory proteins. Nature 329:75-79. CrossRef Medline

Koek W, Patoiseau JF, Assié MB, Cosi C, Kleven MS, Dupont-Pasquelle E, Carilla-Durand E, Palmier C, Valentijn JP, John G, Pauwels PJ, Tarayre JP, Colpaert FC (1998) F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential. J Pharmacol Exp Ther 287: 266-283. Medline

Kraft JB, Peters EJ, Slager SL, Jenkins GD, Reinalda MS, McGrath PJ, Hamilton SP (2007) Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol Psychiatry 61:734-742. CrossRef Medline

Kranz GS, Kasper S, Lanzenberger R (2010) Reward and the serotonergic system. Neuroscience 166:1023-1035. CrossRef Medline

Lemone S, Rogaeva A, Albert PR (2004) Cell type-dependent recruitment of trichostatin A-sensitive repression of the human 5-HT1A receptor gene. J Neurochem 88:857-868. Medline

Lemone S, Turecki G, Bakish D, Du L, Hrdina PD, Bown CD, Sequeira A, Kushwaha N, Morris SJ, Basak A, Ou X-M, Albert PR (2003) Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci 23:8788-8799. Medline

Lesch K-P, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Müller CR, Hamer DH, Murphy DL (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274:1527-1531. Medline

Lladó-Pellort L, Assié MB, Newman-Tancredi A, Artigas F, Celada P (2010) Preferential in vivo action of F15599, a novel 5-HT(1A) receptor agonist, at postsynaptic 5-HT(1A) receptors. Br J Pharmacol 160:1929-1940. CrossRef Medline

Maier W, Zobel A (2008) Contribution of allelic variations to the phenotype of response to antidepressants and antipsychotics. Eur Arch Psychiatry Clin Neurosci 258 [Suppl1]:12-20. CrossRef Medline

Malaguti A, Rossini D, Lucca A, Magri L, Lorenzi C, Pirovano A, Colombo C, Smeraldi E, Zanardi R (2011) Role of COMT, 5-HT1A, and SERT genetic polymorphisms on antidepressant response to transcranial magnetic stimulation. Depress Anxiety 28:568-573. CrossRef Medline

Martinovich K, Lu B (2008) Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology 33:73-83. CrossRef Medline

Mathews TA, Fedele DE, Coppelli FM, Avila AM, Murphy DL, Andrews AM (2004) Gene dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced serotonin transporter expression. J Neurosci Methods 140:169-181. CrossRef Medline

Miller JM, Brennan KG, Ogden TR, Oquendo MA, Sullivan GM, Mann JJ, Parsey RV (2009) Elevated serotonin 1A binding in remitted major depressive disorder: evidence for a trait biological abnormality. Neuropsychopharmacology 34:2275-2284. CrossRef Medline

Montañez S, Owens WA, Gould SG, Murphy DL, Dawes LC (2003) Exaggerated effect of fluvoxamine in heterozygote serotonin transporter knockout mice. J Neurochem 86:210-219. Medline

Murphy D, Lerner A, Rudnick G, Lesch KP (2004) Serotonin transporter: gene, genetic disorders, and pharmacogenetics. Mol Interv 4:109-123. CrossRef Medline

Murphy D, Andrews AM, Wichems CH, Li Q, Tohda M, Greenberg B (1998) Brain serotonin neurotransmission: an overview and update with an emphasis on serotonin subsystem heterogeneity, multiple receptors, interactions with other neurotransmitter systems, and consequent implications for understanding the actions of serotonergic drugs. J Clin Psychopharmacol 18:15:4-12. Medline

Murphy D, Li Q, Engel S, Wichems C, Andrews A, Lesch K-P, Uhl G (2001) Genetic perspectives on the serotonin transporter. Brain Res Bull 56:487-494. Medline

Murphy DL, Maile MS, Vogt NM (2013) 5HTTLPR: white knight or dark blight? ACS Chem Neurosci 4:13-15. CrossRef Medline
Murphy L, Lesch K-P (2008) Targeting the murine serotonin transporter: insights into human neurobiology. Nat Rev Neurosci 9:85-96. CrossRef Medline

Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM (2002) Neurobiology of depression. Neuron 34:13-25. Medline

Ogdere, Z, Talati, A, Hamilton, SP, Levinson, DF, & Weissman, MM (2013) Genotyping serotonin transporter polymorphisms 5-HTTLPR and rs25531 in European-and African-American subjects from the National Institute of Mental Health’s Collaborative Center for Genomic Studies. Transl psychiatry, 3, e307. CrossRef Medline

Ou X-M, Jafar-Nejad H, Storryng JM, Meng J-H, Lemonde S, Albert PR (2000) Novel dual repressor elements for neuronal cell-specific transcription of the rat 5-HT1A receptor gene. J Biol Chem 275: 8161-8168. Medline

Papakostas GI, Petersen TJ, Nierenberg AA, Murakami JL, Alpert JE, Rosenbaum JF, Fava M (2004) Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 65:217-221. Medline

Papakostas GI, Worthington JJ, Josifescu DV, Kinrys G, Burns AM, Fisher LB, Homber ger CH, Mischounol D, Fava M (2006) The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. Depress Anxiety 23:178-181. CrossRef Medline

Parks CL, Shenk T (1996) The serotonin 1A receptor gene contains a TATA-less promoter that responds to MAZ and Sp1. J Biol Chem 271:4417-4430. Medline

Parsley R, Oquendo M, Todd Ogden R, Olvet D, Simpson N, Huang Y, Van Heer tum R, Arango V, Mann J (2006a) Altered serotonin 1A binding in major depression: a [carbonyl-C-11] WAY100635 positron emission tomography study. Biol Psychiatry 59:106-113. Parsley R, Ovet D, Olendo M, Huang Y, Ogden R, Mann J (2006b) Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study. Neuropsychopharmacology 31:1745-1749.

Parsley R, Todd Ogden R, Miller J, Tin A, Hesselgrave N, Goldstein E, Mikhail A, Milak M, Zanderigo F, Sullivan G, Oquendo M, Mann J (2010) Higher serotonin 1A binding in a second major depression cohort: modeling and reference region considerations. Biol Psychiatry 68:170-178. CrossRef

Peyron C, Petit JM, Rampon C, Jouvet M, Luppi PH (1998) Forebrain afferents to the rat dorsal raphe nucleus demonstrated by retrograde and anterograde tracing methods. Neuroscience 82:443-468. Medline

Pittenger C, Duman RS (2008) Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 33:88-109. CrossRef Medline

Porcelli S, Fabbi C, Serretti A (2012) Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol 22:239-258. CrossRef

Rausch J, Johnson M, Fei Y, Li J, Shendarkar N, Mac Hobby H, Ganapathy V, Leibach FH (2002) Initial condition of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol Psychiatry 51:723-732. CrossRef

Raid M, Garcia S, Watkins KC, Jodoin N, Doucet E, Langlois X, El Mestikawy S, Hamon M, Descars L (2000) Somatodendritic localization of 5-HT1A and preterminal axonal localization of 5-HT1B serotonin receptors in adult rat brain. J Comp Neurol 417:181-194. Medline

Richardson-Jones J, Craige C, Nguyen T, Kung H, Gardier A, Dranosvky A, David D, Gudiar B, Beck S, Hen R, Leonardo ED (2011) Serotonin-1A autoreceptors are necessary and sufficient for the normal formation of circuits underlying innate anxiety. J Neurosci 31:6008-6018. CrossRef

Richardson-Jones J, Craige C, Gudiar B, Stephen A, Metzer K, Kung H, Gardier A, Dranosvky A, David D, Beck S, Hen R, Leonardo E (2010) 5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants. Neuron 65:40-52. CrossRef Medline

Risch N, Herrell R, Lehner T, Liang KY, Eaves L, Hoh J, Grieim A, Kovacs M, Ott J, Merikangas KR (2009) Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. JAMA 301:2462-2471. CrossRef Medline

Rothondo A, Nielsen DA, Nakahai B, Hulihan-Giblin B, Bolos A, Goldman D (1997) Agonist-promoted down-regulation and functional desensitization in two naturally occurring variants of the human serotonin1A receptor. Neuropsychopharmacology 17:18-26. CrossRef

Sargent PA, Kjaer KH, Bench CJ, Rabiner EA, Messa C, Meyer J, Gunn R, Grasby PM, Cowen PJ (2000) Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 57:174-180. CrossRef Medline

Serretti A, Kato M, De Ronchi D, Kinoshita T (2007) Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 12:247-257. CrossRef Medline

Serretti A, Artioli P, Lorenzi C, Pirovano A, Tubazio V, Zanardi R (2004) The C(--1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. Int J Psychopharmacol 7:453-460. CrossRef Medline

Serretti A, Chiesa A, Calati R, Perna G, Bellodi L, De Ronchi D (2009) Common genetic, clinical, demographic and psychosocial predictors of response to pharmacotherapy in mood and anxiety disorders. Int Clin Psychopharmacol 24:1-18. CrossRef Medline

Shen GW, Hugino Y, Kobayashi H, Shinohara-Tanaka K, Ikeda K, Yamamoto H, Yamamoto T, Lesch KP, Murphy DL, Hall FS, Uhl GR, Sora I (2004) Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters. Neuropsychopharmacology 29:1790-1799. CrossRef Medline

Shenoy SK, Lefkowitz RJ (2003) Multifaceted roles of beta-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling. Biochem J 375:503-515. CrossRef Medline

Smiraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalan M (1998) Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 3:508-511. Medline

Smits KM, Smits LJ, Schouten JS, Stelma FF, Nelemans P, Prins MH (2004) Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol Psychiatry 9:433-441. CrossRef Medline

Sotelo C, Cholle B, El Mestikawa S, Goezian H, Hamon M (1990) Direct immunohistochemical evidence of the existence of 5-HT1A autoreceptors on serotoninergic neurons in the midbrain raphe nuclei. Eur J Neurosci 2:1144-1154. Medline

Steiner W, Muller B, Leucht S, Kissling W (2001) Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. Clin Chim Acta 308:33-41. Medline

Stockmeier CA, Shapiro LA, Dilley GE, Kolli TN, Friedman L, Rajkowska G (1998) Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression—postmortem evidence for decreased serotonin activity. J Neurosci 18:7394-7401.

Suzuki Y, Sawamura K, Someya T (2004) The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients. Pharmacogenomics J 4:283-286. CrossRef Medline

Tauscher J, Verhoeft NP, Christensen BK, Hussey D, Meyer J, Bosch J, Rosenbaum JF, Homberger CH, Mischoulon D, Fava M (2002) The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. Depress Anxiety 23:178-181. CrossRef
Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM, Luther JF, Shores-Wilson K, Rush AJ (2006) Medication augmentation after the failure of SSRIs for depression. N Engl J Med 354:1243-1252. CrossRef Medline

Uher R, McGuffin P (2010) The moderation by the serotonin transporter gene of environmental adversity in the etiology of depression: 2009 update. Mol Psychiatry 15:18-22. CrossRef Medline

Vasudeva RK, Lin RCS, Simpson KL, Waterhouse BD (2011) Functional organization of the dorsal raphe efferent system with special consideration of nitrergic cell groups. J Chem Neuroanat 41:281-293. CrossRef Medline

Wang PS, Simon G, Kessler RC (2003) The economic burden of depression and the cost-effectiveness of treatment. Int J Methods Psychiatr Res 12:22-33. Medline

Wilkie MJV, Smith G, Day RK, Matthews K, Smith D, Blackwood D, Reid IC, Wolf CR (2008) Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. Pharmacogenomics J 9:61-70. CrossRef

Xu Z, Zhang Z, Shi Y, Pu M, Yuan Y, Zhang X, Li L, Reynolds GP (2012) Influence and interaction of genetic polymorphisms in the serotonin system and life stress on antidepressant drug response. J Psychopharmacol 26:349-359. CrossRef Medline

Yatham LN, Liddle PF, Sossi V, et al. (2012) Positron emission tomography study of the effects of tryptophan depletion on brain serotonin(2) receptors in subjects recently remitted from major depression. Arch Gen Psychiatry 69:601-609. CrossRef

Young SN (2013) Acute tryptophan depletion in humans: a review of theoretical, practical and ethical aspects. J Psychiatry Neurosci 38:294-305. CrossRef Medline

Zhang K, Xu Q, Xu Y, Yang H, Luo J, Sun Y, Sun N, Wang S, Shen Y (2009) The combined effects of the 5-HTTLPR and 5-HTR1A genes modulates the relationship between negative life events and major depressive disorder in a Chinese population. J Affect Disord 114:224-231. CrossRef